Skip to main content
Top
Published in: Breast Cancer Research 5/2005

Open Access 01-10-2005 | Research article

Greatly increased occurrence of breast cancers in areas of mammographically dense tissue

Authors: Giske Ursin, Linda Hovanessian-Larsen, Yuri R Parisky, Malcolm C Pike, Anna H Wu

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

Introduction

Mammographic density is a strong, independent risk factor for breast cancer. A critical unanswered question is whether cancers tend to arise in mammographically dense tissue (i.e. are densities directly related to risk or are they simply a marker of risk). This question cannot be addressed by studying invasive tumors because they manifest as densities and cannot be confidently differentiated from the densities representing fibrous and glandular tissue. We addressed this question by studying ductal carcinoma in situ (DCIS), as revealed by microcalcifications.

Method

We studied the cranio-caudal and the mediolateral-oblique mammograms of 28 breasts with a solitary DCIS lesion. Two experienced radiologists independently judged whether the DCIS occurred in a mammographically dense area, and determined the density of different areas of the mammograms.

Results

It was not possible to determine whether the DCIS was or was not in a dense area for six of the tumors. Of the remaining 22 lesions, 21 occurred in dense tissue (test for difference from expected taken as the percentage of density of the 'mammographic quadrant' containing DCIS; P < 0.0001). A preponderance of DCIS (17 out of 28) occurred in the mammographic quadrant with the highest percentage density.

Conclusion

DCIS occurs overwhelmingly in the mammographically dense areas of the breast, and pre-DCIS mammograms showed that this relationship was not brought about by the presence of the DCIS. This strongly suggests that some aspect of stromal tissue comprising the mammographically dense tissue directly influences the carcinogenic process in the local breast glandular tissue.
Literature
1.
go back to reference Saftlas AF, Szklo M: Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev. 1987, 9: 146-174.CrossRefPubMed Saftlas AF, Szklo M: Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev. 1987, 9: 146-174.CrossRefPubMed
2.
go back to reference Oza AM, Boyd NF: Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev. 1993, 15: 196-208.CrossRefPubMed Oza AM, Boyd NF: Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev. 1993, 15: 196-208.CrossRefPubMed
3.
go back to reference Warner E, Lockwood G, Tritchler D, Boyd NF: The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev. 1992, 16: 67-72.PubMed Warner E, Lockwood G, Tritchler D, Boyd NF: The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev. 1992, 16: 67-72.PubMed
4.
go back to reference Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ: Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 12: 1133-1144. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ: Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 12: 1133-1144.
5.
go back to reference Brisson J, Merletti F, Sadowsky NL, Twaddle JA, Morrison AS, Cole P: Mammographic features of the breast and breast cancer risk. Am J Epidemiol. 1982, 115: 428-437.CrossRefPubMed Brisson J, Merletti F, Sadowsky NL, Twaddle JA, Morrison AS, Cole P: Mammographic features of the breast and breast cancer risk. Am J Epidemiol. 1982, 115: 428-437.CrossRefPubMed
6.
go back to reference Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ: Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995, 87: 670-675.CrossRefPubMed Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ: Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995, 87: 670-675.CrossRefPubMed
7.
go back to reference Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: Mammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst. 1995, 87: 1622-1629.CrossRefPubMed Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: Mammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst. 1995, 87: 1622-1629.CrossRefPubMed
8.
go back to reference Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC: Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. 2003, 12: 332-338.PubMed Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC: Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. 2003, 12: 332-338.PubMed
9.
go back to reference Page DL, Rogers LW, Schuyler PA, Dupont WD, Jensen RA: The natural history of ductal carcinoma in situ of the breast. Ductal Carcinoma In Situ of the Breast. Edited by: Silverstein MJ, Recht A, Lagios MD. 2002, Philadelphia, PA: Lippincott, Williams and Wilkins, 17-21. Page DL, Rogers LW, Schuyler PA, Dupont WD, Jensen RA: The natural history of ductal carcinoma in situ of the breast. Ductal Carcinoma In Situ of the Breast. Edited by: Silverstein MJ, Recht A, Lagios MD. 2002, Philadelphia, PA: Lippincott, Williams and Wilkins, 17-21.
10.
go back to reference Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH: Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003, 5: R129-R135. 10.1186/bcr622.CrossRefPubMedPubMedCentral Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH: Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003, 5: R129-R135. 10.1186/bcr622.CrossRefPubMedPubMedCentral
11.
go back to reference Barcellos-Hoff MH, Medina D: New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res. 2005, 7: 33-36. 10.1186/bcr972.CrossRefPubMed Barcellos-Hoff MH, Medina D: New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res. 2005, 7: 33-36. 10.1186/bcr972.CrossRefPubMed
12.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al: Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al: Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed
13.
go back to reference Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J: Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev. 2000, 9: 911-915.PubMed Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J: Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev. 2000, 9: 911-915.PubMed
14.
go back to reference Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW: Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004, 96: 621-628.CrossRefPubMed Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW: Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004, 96: 621-628.CrossRefPubMed
15.
go back to reference Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Womens Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRef Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Womens Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRef
16.
go back to reference Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G: Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003, 95: 30-37.CrossRefPubMed Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G: Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003, 95: 30-37.CrossRefPubMed
Metadata
Title
Greatly increased occurrence of breast cancers in areas of mammographically dense tissue
Authors
Giske Ursin
Linda Hovanessian-Larsen
Yuri R Parisky
Malcolm C Pike
Anna H Wu
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1260

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine